Literature DB >> 34907516

The Probable Protective Effect of Photobiomodulation on the Inflammation of the Airway and Lung in COVID-19 Treatment: A Preclinical and Clinical Meta-Analysis.

Hanieh Raji1, Babak Arjmand2,3, Fakher Rahim4,5.   

Abstract

Preliminary studies also show that many of the fatalities of COVID-19 are due to over-activity of the immune system, and photobiomodulation (PBM) therapy mainly accelerates wound healing and reduces pain and inflammation. Therefore, this systematic review and meta-analysis was conducted to evaluate the probable effect of the PBM therapy on the lung inflammation or ARDS and accelerate the regeneration of the damaged tissue. We systematically searched major indexing databases, including PubMed/Medline, ISI web of science (WOS), Scopus, Embase, and Cochrane central, using standard terms without any language, study region, or type restrictions. Of the 438 studies found through initial searches, 13 met the inclusion criteria. After applying the exclusion criteria, the main properties of 13 articles on 384 animals included in this meta-analysis with a wide range of species include rat (n = 10) and rabbit (n = 3). The analysis revealed that PBM therapy reduced TNFα (SMD:-3.75, 95% CI: -4.49, -3.02, P < 0.00001, I2 = 10%), IL-1β (SMD:-4.65, 95% CI: -6.15, -3.16, P < 0.00001, I2 = 62%), and IL-6 (SMD:-4.20, 95% CI: -6.42, -1.97, P = 0.0002, I2 = 88%) significantly compared with the model controls. Hence, PBM therapy increased IL-10 significantly compared with the model controls (SMD:-4.65, 95% CI: -6.15, -3.16, P < 0.00001, I2 = 62%). PBM therapy also reduced MPO activity (SMD:-2.13, 95% CI: -3.38, -0.87, P = 0.0009, I2 = 64%) and vascular permeability (SMD:-2.59, 95% CI: -4.40, -0.77, P = 0.0052, I2 = 71%) in the lung using the Evans blue extravasation technique significantly compared with the model controls. This systematic review and meta-analysis revealed that the PBM therapy does utilize beneficial anti-inflammatory effect, modulation of the immune system, lung permeability, or bronchoalveolar lavage on lung damage in both animal models and clinical studies. However, animal model and clinical studies appear limited considering the quality of the included evidences; therefore, large clinical trials are still required.
© 2021. Springer Nature Switzerland AG.

Entities:  

Keywords:  Anti-inflammatory; COVID-19; Meta-analysis; SARS-CoV-2

Mesh:

Year:  2022        PMID: 34907516     DOI: 10.1007/5584_2021_665

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  50 in total

1.  Effect of LLLT Ga-Al-As (685 nm) on LPS-induced inflammation of the airway and lung in the rat.

Authors:  F Aimbire; R Albertine; R G de Magalhães; R A B Lopes-Martins; H C Castro-Faria-Neto; R A Zângaro; M C Chavantes; M T T Pacheco
Journal:  Lasers Med Sci       Date:  2005-06-18       Impact factor: 3.161

2.  Low-level laser therapy induces dose-dependent reduction of TNFalpha levels in acute inflammation.

Authors:  F Aimbire; R Albertini; M T T Pacheco; H C Castro-Faria-Neto; P S L M Leonardo; V V Iversen; R A B Lopes-Martins; J M Bjordal
Journal:  Photomed Laser Surg       Date:  2006-02       Impact factor: 2.796

3.  Photobiomodulation of inflammatory-cytokine-related effects in a 3-D culture model with gingival fibroblasts.

Authors:  Laís Medeiros Cardoso; Taisa Nogueira Pansani; Josimeri Hebling; Carlos Alberto de Souza Costa; Fernanda Gonçalves Basso
Journal:  Lasers Med Sci       Date:  2020-02-07       Impact factor: 3.161

4.  Low level laser therapy (LLLT) decreases pulmonary microvascular leakage, neutrophil influx and IL-1beta levels in airway and lung from rat subjected to LPS-induced inflammation.

Authors:  F Aimbire; A P Ligeiro de Oliveira; R Albertini; J C Corrêa; C B Ladeira de Campos; J P Lyon; J A Silva; M S Costa
Journal:  Inflammation       Date:  2008-04-18       Impact factor: 4.092

5.  Low-Level Laser Therapy Reduces Lung Inflammation in an Experimental Model of Chronic Obstructive Pulmonary Disease Involving P2X7 Receptor.

Authors:  Gabriel da Cunha Moraes; Luana Beatriz Vitoretti; Auriléia Aparecida de Brito; Cintia Estefano Alves; Nicole Cristine Rigonato de Oliveira; Alana Dos Santos Dias; Yves Silva Teles Matos; Manoel Carneiro Oliveira-Junior; Luis Vicente Franco Oliveira; Renata Kelly da Palma; Larissa Carbonera Candeo; Adriana Lino-Dos-Santos-Franco; Anna Carolina Ratto Tempestine Horliana; João Antonio Gimenes Júnior; Flavio Aimbire; Rodolfo Paula Vieira; Ana Paula Ligeiro-de-Oliveira
Journal:  Oxid Med Cell Longev       Date:  2018-03-04       Impact factor: 6.543

6.  Hypercytokinemia in COVID-19: Tear cytokine profile in hospitalized COVID-19 patients.

Authors:  Barbara Burgos-Blasco; Noemi Güemes-Villahoz; Jose Luis Santiago; Jose Ignacio Fernandez-Vigo; Laura Espino-Paisán; Beatriz Sarriá; Julian García-Feijoo; Jose Maria Martinez-de-la-Casa
Journal:  Exp Eye Res       Date:  2020-09-16       Impact factor: 3.467

Review 7.  Corona Viruses: A Review on SARS, MERS and COVID-19.

Authors:  Nihala Naseefa Chathappady House; Sheeba Palissery; Honey Sebastian
Journal:  Microbiol Insights       Date:  2021-03-19

8.  The right place for IL-1 inhibition in COVID-19.

Authors:  Giulio Cavalli; Lorenzo Dagna
Journal:  Lancet Respir Med       Date:  2021-01-22       Impact factor: 30.700

Review 9.  SARS-CoV-2 infection: The role of cytokines in COVID-19 disease.

Authors:  Víctor J Costela-Ruiz; Rebeca Illescas-Montes; Jose M Puerta-Puerta; Concepción Ruiz; Lucia Melguizo-Rodríguez
Journal:  Cytokine Growth Factor Rev       Date:  2020-06-02       Impact factor: 7.638

10.  COVID-19 pulmonary pathology: a multi-institutional autopsy cohort from Italy and New York City.

Authors:  Alain C Borczuk; Fiorella Calabrese; Mary Beth Beasley; Steven P Salvatore; Surya V Seshan; Sanjay S Patel; James B Bussel; Maria Mostyka; Sarah Elsoukkary; Bing He; Claudia Del Vecchio; Francesco Fortarezza; Federica Pezzuto; Paolo Navalesi; Andrea Crisanti; Mary E Fowkes; Clare H Bryce
Journal:  Mod Pathol       Date:  2020-09-02       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.